Inventor · disambiguated record
Daniel D. Long
Also filed as: LONG DANIEL D · MARQUESS DANIEL
104 granted patents·7 pending applications·873 citations·filing 2002–2024
99Inventor score
Files withTHERAVANCE INC37THERAVANCE BIOPHARMA R&D IP LLC31LONG DANIEL D10MARQUESS DANIEL6MCKINNELL ROBERT MURRAY5
Top patents by PatentIndex Score
111 records- 0197US7622508B28-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsTHERAVANCE INC·Filed 2007·Granted Nov 24, 2009·39 cites·19 claims
- 0297US7375114B2Quinolinone-carboxamide compounds as 5-HT4 receptor agonistsTHERAVANCE INC·Filed 2005·Granted May 20, 2008·41 cites·17 claims
- 0397US7341993B2Cross-linked glycopeptide—cephalosporin antibioticsTHERAVANCE INC·Filed 2005·Granted Mar 11, 2008·22 cites·2 claims
- 0497US6974797B2Cross-linked glycopeptide-cephalosporin antibioticsTHERAVANCE INC·Filed 2002·Granted Dec 13, 2005·45 cites·25 claims
- 0596US11634419B2Dimethyl amino azetidine amides as JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Apr 25, 2023·6 cites·20 claims
- 0696US8604058B24-[2-(2-fluorophenoxymethyl)phenyl]piperidine compoundsPATTERSON LORI JEAN·Filed 2012·Granted Dec 10, 2013·20 cites·24 claims
- 0796US8304432B24-[2-(2-fluorophenoxymethyl)phenyl]piperidine compoundsPATTERSON LORI JEAN·Filed 2009·Granted Nov 6, 2012·25 cites·26 claims
- 0896US7612037B2Cross-linked glycopeptide-cephalosporin antibioticsTHERAVANCE INC·Filed 2007·Granted Nov 3, 2009·18 cites·13 claims
- 0996US7332471B2Cross-linked glycopeptide-cephalosporin antibioticsTHERAVANCE INC·Filed 2006·Granted Feb 19, 2008·21 cites·23 claims
- 1095US10947229B2Dimethyl amino azetidine amides as JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Mar 16, 2021·10 cites·15 claims
- 1195US10836763B25 to 7 membered heterocyclic amides as JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Nov 17, 2020·12 cites·20 claims
- 1295US9162982B24-[2-(2-fluorophenoxy methyl)phenyl]piperidine compoundsPATTERSON LORI JEAN·Filed 2013·Granted Oct 20, 2015·15 cites·20 claims
- 1395US7067481B2Cross-linked glycopeptide-cephalosporin antibioticsTHERAVANCE INC·Filed 2004·Granted Jun 27, 2006·41 cites·35 claims
- 1495US6878686B2Cross-linked glycopeptide-cephalosporin antibioticsTHERAVANCE INC·Filed 2003·Granted Apr 12, 2005·49 cites·27 claims
- 1594US11155549B2Ester and carbonate pyrimidine compounds as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Oct 26, 2021·5 cites·26 claims
- 1694US9663509B28-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsLONG DANIEL D·Filed 2015·Granted May 30, 2017·10 cites·2 claims
- 1794US8263618B28-azabicyclo[3.2.1]octane compounds as MU opioid receptor antagonistsLONG DANIEL D·Filed 2009·Granted Sep 11, 2012·18 cites·15 claims
- 1894US7759363B2Benzimidazole-carboxamide compounds as 5-HT4, receptor agonistsTHERAVANCE INC·Filed 2006·Granted Jul 20, 2010·18 cites·18 claims
- 1994US7691878B2Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsTHERAVANCE INC·Filed 2008·Granted Apr 6, 2010·13 cites·19 claims
- 2094US7396933B2Quinolinone-carboxamide compoundsTHERAVANCE INC·Filed 2005·Granted Jul 8, 2008·28 cites·13 claims
- 2194US7351704B2Indazole-carboxamide compounds as 5-HT4 receptor agonistsTHERAVANCE INC·Filed 2005·Granted Apr 1, 2008·25 cites·19 claims
- 2293US8664242B28-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsLONG DANIEL D·Filed 2012·Granted Mar 4, 2014·13 cites·6 claims
- 2393US7728006B2Quinolinone-carboxamide compounds as 5-HT4 receptor agonistsTHERAVANCE INC·Filed 2005·Granted Jun 1, 2010·11 cites·18 claims
- 2493US7592355B2Quinolinone-carboxamide compounds as 5-HT, receptor agonistsTHERAVANCE INC·Filed 2007·Granted Sep 22, 2009·13 cites·20 claims
- 2593US7419989B2Indazole-carboxamide compoundsTHERAVANCE INC·Filed 2005·Granted Sep 2, 2008·19 cites·12 claims
- 2693US7399862B25-HT4 receptor agonist compoundsTHERAVANCE INC·Filed 2005·Granted Jul 15, 2008·26 cites·12 claims
- 2793US6995138B2Cross-linked glycopeptide-cephalosporin antibioticsTHERAVANCE INC·Filed 2004·Granted Feb 7, 2006·34 cites·6 claims
- 2892US9206172B28-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsLONG DANIEL D·Filed 2014·Granted Dec 8, 2015·10 cites·2 claims
- 2992US8927573B28-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsLONG DANIEL D·Filed 2014·Granted Jan 6, 2015·10 cites·15 claims
- 3092US8377964B2Benzimidazole-carboxamide compounds as 5-HT4 receptor agonistsTHERAVANCE INC·Filed 2010·Granted Feb 19, 2013·10 cites·17 claims
- 3192US7902220B28-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonistsTHERAVANCE INC·Filed 2008·Granted Mar 8, 2011·14 cites·14 claims
- 3292US7763637B2Quinolinone-carboxamide compounds as 5-HT4, receptor agonistsTHERAVANCE INC·Filed 2008·Granted Jul 27, 2010·12 cites·19 claims
- 3392US7317022B2Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonistsTHERAVANCE INC·Filed 2006·Granted Jan 8, 2008·19 cites·15 claims
- 3491US10745394B28-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Aug 18, 2020·2 cites·11 claims
- 3591US10081626B28-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Sep 25, 2018·5 cites·7 claims
- 3691US8247559B2Process for preparing an intermediate to mu opioid receptor antagonistsCOLSON PIERRE-JEAN·Filed 2011·Granted Aug 21, 2012·8 cites·2 claims
- 3791US7932402B2Process for preparing an intermediate to opioid receptor antagonistsTHERAVANCE INC·Filed 2008·Granted Apr 26, 2011·8 cites·18 claims
- 3890US7534889B25-HT4 receptor agonist compoundsTHERAVANCE INC·Filed 2008·Granted May 19, 2009·13 cites·16 claims
- 3989US10961267B2Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Mar 30, 2021·3 cites·18 claims
- 4089US10377751B28-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Aug 13, 2019·3 cites·2 claims
- 4189US8143279B2Benzimidazole-carboxamide compounds as 5-HT4 receptor agonistsMCKINNELL ROBERT MURRAY·Filed 2006·Granted Mar 27, 2012·9 cites·8 claims
- 4288US11548887B28-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Jan 10, 2023·1 cites·16 claims
- 4388US9428489B2Benzimidazole-carboxamide compounds as 5-HT4 receptor agonistsMCKINNELL ROBERT MURRAY·Filed 2014·Granted Aug 30, 2016·6 cites·8 claims
- 4488US8575192B2Quinolinone-carboxamide compounds as 5-HT4 receptor agonistsMARQUESS DANIEL·Filed 2012·Granted Nov 5, 2013·6 cites·18 claims
- 4588US7947710B2Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsTHERAVANCE INC·Filed 2008·Granted May 24, 2011·9 cites·15 claims
- 4688US7498442B2Quinolinone-carboxamide compoundsTHERAVANCE INC·Filed 2008·Granted Mar 3, 2009·10 cites·10 claims
- 4788US7446114B2Quinolinone compounds as 5-HT4 receptor agonistsTHERAVANCE INC·Filed 2006·Granted Nov 4, 2008·10 cites·15 claims
- 4888US2024316024A14-[2-(2-fluorophenoxymethyl)phenyl]piperidine compoundsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2024·Application pending·0 cites
- 4987US8962653B2Quinolinone-carboxamide compounds as 5-HT4 receptor agonistsMARQUESS DANIEL·Filed 2013·Granted Feb 24, 2015·5 cites·11 claims
- 5086US12398135B2Dimethyl amino azetidine amides as JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2024·Granted Aug 26, 2025·0 cites·6 claims
Showing the top 50 of 111 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Daniel D. Long files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →